Peptides A-Z · Research Guide
This article clarifies what people mean when they ask "Is SS-31 legal?" It explains the names used for the compound, summarizes where the molecule was approved or limited as of…
The guide is written for researchers, biohackers and informed consumers who want a clear, evidence-backed overview without medical advice. It separates regulatory approval status from the availability of research-grade material and points readers to the primary regulator registers for verification.
ss 31 peptide is the short name commonly used for the compound also known by the international nonproprietary name elamipretide, and the molecule is sometimes promoted under a brand name in specific markets. People ask about ss 31 peptide because the same molecule appears in both research catalogs and in regulated drug filings, and those different contexts affect how it can legally be obtained or prescribed.
The molecule targets mitochondria, and early clinical and preclinical research has explored its effects on cellular energy processes and mitochondrial function, which explains why it appears in both laboratory research and clinical development literature. When you search registries or supplier pages, the same compound may be listed as SS-31, elamipretide or by a brand name, so matching names matters when checking legal status and product labels. For background on peptides see what are peptides.
To avoid confusion, note that in the United States the marketed product name for an approved formulation is Forzinity, while many research suppliers continue to list the compound as SS-31 or elamipretide for research use only.
When discussing legality, it helps to keep two threads separate: the regulatory approval status that governs clinical prescribing and the availability of research-grade material sold to laboratories. The two are not interchangeable, and each carries different legal and practical implications.
Summary: in the United States elamipretide, branded as Forzinity, received regulatory approval on 2025-09-19 and is a prescription medicine there; in the European Union, the United Kingdom and Canada, no central or national market authorisation was in place across those regions as of early 2026, so routine prescription access was not generally available. Coverage of the regulatory timeline appeared in trade press such as Biopharma Dive.
In the U.S., FDA approval means the product is on the market as a regulated prescription medicine and has an approved label that governs clinical use and distribution Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Across the EU there was no central marketing authorisation for elamipretide listed in the EMA public database by early 2026, which means that, absent national approvals, access in member states would usually depend on clinical trials or specific national pathways rather than routine prescribing European Medicines Agency medicines database. Analysis of the approval context is available from industry outlets such as Labiotech.
Similarly, the national regulators in the UK and Canada had not recorded a marketing authorisation for elamipretide as of early 2026, so access in those countries depended on named-patient, special-access or trial routes rather than general prescription availability MHRA UK medicines register and guidance.
Start by checking the national regulator’s marketing-authorisation or licensed medicines register for your country. For the United States, the FDA Drugs@FDA pages and the FDA press announcements list approvals and the official prescribing information; similar registers exist at the EMA, MHRA and Health Canada sites and should be your primary source for current authorisation status Long-term efficacy and safety of elamipretide in patients with Barth syndrome (TAZPOWER extension).
Practical search steps: search for the active substance name and common synonyms on the regulator site, then look for the approved product name and the published label or summary of product characteristics. Also search clinical trial registries and manufacturer press releases for recent developments or special-access notices.
Legal access depends on national approvals: Forzinity/elamipretide is FDA-approved in the U.S., but the EU, UK and Canada lacked central or national marketing authorisations as of early 2026; verify with your national regulator and trial registries.
Red flags include vendor pages that market a product for human use without referencing a national marketing authorisation, product listings marked only as ‘for research use only’, and supplier claims that imply routine clinical availability without citing regulator documentation. Treat such pages as prompts to verify, not as proof of legal status.
The FDA approved Forzinity, a formulation of elamipretide, on 2025-09-19 and that approval makes the product a regulated prescription medicine in the United States. The approval places the product on the U.S. market subject to the terms of the approval and the conditions stated in the official label Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Practically, FDA approval means there is an approved prescribing information document that defines the authorised indication, dosing, contraindications and safety monitoring expectations. Clinicians and dispensing pharmacies rely on that label when prescribing and supplying the medicine, and payers and hospitals use it to guide reimbursement and formulary decisions Long-term efficacy and safety of elamipretide in patients with Barth syndrome (TAZPOWER extension). The company published its own announcement at the same time Stealth BioTherapeutics announcement.
Approval does not remove ordinary medical oversight: prescribing, dispensing and insurance coverage remain subject to clinical judgement, the approved indication, and the healthcare system’s rules. For researchers in the United States, having an approved product may simplify some study designs, but research use and clinical prescribing are still governed by protocol and institutional review processes.
The EMA had not issued a central EU marketing authorisation for elamipretide by early 2026, which means there was no single approval that covers all EU member states. In practice, absence of central authorisation requires either national approvals in individual member states or alternative access routes such as clinical trials or compassionate use programs European Medicines Agency medicines database.
If a company seeks EU-wide marketing, it typically files an application with the EMA; without that central marketing authorisation the manufacturer may still seek licences country by country or provide access through study protocols and named-patient schemes, but those options vary by member state.
Because national competent authorities set their own procedures for named-patient access and compassionate use, availability and timelines can differ substantially between countries. For people in EU member states this means checking the national regulator and trial registries for the latest options and not assuming a uniform EU position.
As of early 2026 the MHRA had not granted a UK marketing authorisation for elamipretide, so routine prescription availability in the UK would depend on any future national licence being issued; otherwise access is typically through clinical trials, named-patient requests or special-access arrangements MHRA UK medicines register and guidance.
Named-patient routes allow clinicians to request unlicensed medicines for individual patients when no suitable authorised alternative exists, but these requests follow regulatory and institutional procedures and are not a substitute for an authorised product. Clinical-trial listings can also provide lawful access while studies are active, and trial registries are an essential source of up-to-date information.
People in the UK should consult MHRA notices and trial registries rather than assuming availability, because national licensing decisions, compassionate-use programmes and trial openings are the usual pathways when a product does not have an ordinary marketing authorisation.
Health Canada did not list elamipretide as an authorised marketed drug in early 2026, which means Canadian patients would typically need to rely on clinical trials or special-access programs to obtain legal access rather than routine prescription-based supply Health Canada drug product database.
Canada’s Special Access Program and clinical trial system are common mechanisms for access to unapproved medicines, but applications under those routes require sponsor or clinician involvement and follow specific criteria and documentation requirements. That process differs from having an authorised marketed product available through pharmacies.
If you are in Canada and considering whether a compound is available to you, check the Health Canada drug product database, search clinical trial registries for active studies, and consult treating clinicians or trial sponsors for practical guidance about access routes and requirements.
Many commercial suppliers list SS-31 or elamipretide as ‘for research use only’, and that label is important: it indicates the material is intended for laboratory research rather than therapeutic use in humans, and selling such material does not by itself make clinical or medicinal use legal in regulated jurisdictions Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. For supplier selection and legal checks see our safety and legality guide.
‘For research use only’ listings may lack the quality assurances, regulatory documentation and authorised labeling that apply to approved medicinal products. Buyers should be cautious about interpreting such listings as permission to use the material clinically, because legal access for patients depends on national marketing authorisations or specific authorised compassionate-use pathways.
Watch for vendor claims that imply routine clinical availability or suggest medical benefits without linking to regulator documentation; those claims are a red flag that requires independent verification with official registries before any purchase or use decision.
A common misunderstanding is assuming that availability in one country implies legality everywhere. An approved prescription product in the United States does not automatically make the same product authorised for prescription or import in other countries, where separate regulatory approvals or permissions may be required European Medicines Agency medicines database.
Another typical error is treating research-grade ‘for research use only’ material as clinically approved; such material is not the same as an authorised medicine and importing or using it for human consumption can expose individuals to seizure of goods by customs and potential legal consequences under local medicines laws.
To reduce risk, verify prescription requirements and import rules with local customs authorities and regulators before attempting to purchase or import a compound, and remember that authorised prescribing requires clinician oversight and adherence to the approved label where one exists.
Immediate verification steps: look up the active substance and product name in the national marketing-authorisation register, read the approved label or summary of product characteristics if present, and note whether the product is prescription only or has special conditions attached to its use Long-term efficacy and safety of elamipretide in patients with Barth syndrome (TAZPOWER extension).
Step 2: search clinical-trial registries and sponsor press releases for ongoing trials or compassionate-use programmes that may provide lawful access. If a sponsor has announced a programme, the announcement and trial listing are primary sources that explain eligibility and application steps.
Step 3: if considering purchase from a supplier, confirm the intended use, check whether the supplier explicitly labels material as ‘for research use only’, and verify import rules and documentation required by your national regulator. If in doubt, seek guidance from a treating clinician or institutional compliance office rather than relying solely on vendor statements.
Patient scenario: if you are a patient in a country where elamipretide has regulatory approval, lawful access normally requires a prescription from a clinician and supply through authorised pharmacies or hospital channels according to the approved label. If you are in a country without national approval, lawful access typically requires participation in a clinical trial or an approved named-patient or compassionate-use mechanism Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Researcher scenario: laboratory use typically relies on research-grade material purchased under ‘for research use only’ terms and on institutional approvals such as ethical review and biosafety oversight. Institutional procurement and regulatory compliance remain essential when working with experimental compounds in a lab setting.
Consumer scenario: if you are a curious consumer considering online purchase, avoid using research-grade material for self-administration. Instead, use regulator registers and trial listings to understand lawful access routes, and consult qualified professionals for clinical questions rather than treating supplier copy as authoritative.
Key points to remember: Forzinity, a formulation of elamipretide, received FDA approval in the United States on 2025-09-19 and is a prescription medicine there, while the European Medicines Agency and several national regulators had not recorded a central EU or UK marketing authorisation by early 2026, and Health Canada had not listed the product as authorised for routine market supply Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Research-grade listings of SS-31 or elamipretide as ‘for research use only’ do not equal medicinal approval, and buying from research suppliers does not replace national marketing authorisations or safe clinical oversight Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Next steps: check the national regulator’s marketing-authorisation register, read the approved product label if present, and consult clinical trial registries and sponsor announcements for current access options. Those primary sources are the best way to confirm whether elamipretide is authorised or accessible in your country.
Import rules vary by country; in many places importing research-grade SS-31 for human use is restricted. Check your national medicines regulator and customs guidance before attempting import.
Forzinity is a branded formulation of elamipretide approved in the United States; SS-31 and elamipretide are names for the same active compound in research contexts.
No. 'For research use only' indicates the product is intended for laboratory research and is not authorised for clinical use or guaranteed safe for human administration.
Bottom line
Regulatory status can change, so treat the information here as a snapshot based on early-2026 sources. Before making any decision about procurement or clinical use, consult the appropriate national regulator entries, the approved product label where present, and trial or sponsor announcements for the most recent guidance.
If you need help locating the correct regulator register for your country, use the checkpoint steps in the checklist section and consider seeking counsel from a qualified clinician or institutional compliance officer.
The 2-minute quiz sorts the research by what you actually want to achieve, then points you to the guides that apply to you.